Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China.

Published in: Expert review of pharmacoeconomics & outcomes research (2023)

Serplulimab plus chemotherapy was unlikely to be the cost-effective first-line strategy compared with chemotherapy alone for patients with ES-SCLC in China. Reduced the price of serplulimab could increase its cost-effective.

Keyphrases

small cell lung cancer
locally advanced
chemotherapy induced
rectal cancer
radiation therapy